Clik here to view.
New NIH rules about conflicts of interest are a swiss cheese of loopholes
The newly announced rules on financial conflicts of interest among federally funded researchers are certainly an improvement on the existing regulations issued by the National Institutes of Health in...
View ArticleClik here to view.
New heart medication study was too flawed for publication, former journal...
At a Harvard event last night honoring the former Grassley investigator Paul Thacker, someone in the audience wanted to know how the topic of Thacker’s talk — Dollars for Doctors: Who owns your...
View ArticleClik here to view.
Drug and medical device industry launches push to weaken FDA oversight
With the Obama administration hobbled by a Republican-led Congress, the pharmaceutical and medical device industry seems to have launched a concerted push to roll back regulatory initiatives designed...
View ArticleClik here to view.
Allegations of fraud and extensive ghostwriting form core of upcoming Texas...
On November 28, the Texas Attorney General is expected to begin a landmark trial against Johnson & Johnson on charges that the pharmaceutical giant “subverted scientific integrity” by paying off...
View ArticleClik here to view.
New drug industry partnership with hospitals could jeopardize patient care
We’ve all signed those vague privacy statements when visiting our local hospital for medical care. But how many of us have actually read the fine print and understand that the most sensitive details...
View ArticleClik here to view.
From the Pentagon Papers to Allen Jones: Why it’s so hard to be a whistleblower
Allen Jones, the whistleblower in an ongoing landmark trial against the pharmaceutical giant Johnson & Johnson, was very much on my mind this past weekend. I was participating in a workshop to...
View Article
